PROGNOSTIC IMPACT OF THE MAXIMAL EVALUABLE LESION SIZE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB COMBINATION THERAPY

被引：0
|
作者：
Mita, Yoshie
Teishima, Jun
Hara, Takuto
Bando, Yukari
Suzuki, Kotaro
Terakawa, Tomoaki
Chiba, Koji
Miyake, Hideaki
机构：
来源：
JOURNAL OF UROLOGY | 2025年 / 213卷 / 5S期
关键词：
D O I：
10.1097/01.JU.0001110068.14710.ff.17
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP28-17
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab
    Kunal Desai
    Landon Brown
    Wei Wei
    Matthew Tucker
    Chester Kao
    Emily Kinsey
    Brian Rini
    Kathryn Beckermann
    Tian Zhang
    Moshe C. Ornstein
    Targeted Oncology, 2021, 16 : 633 - 642
  • [22] A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.
    Pili, Roberto
    Adra, Nabil
    Logan, Theodore F.
    Burney, Heather
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [23] Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma
    Hashimoto, Mamoru
    Nakayama, Takahito
    Fujimoto, Saizo
    Inoguchi, Shunsuke
    Nishimoto, Mitsuhisa
    Kikuchi, Takashi
    Adomi, Shogo
    Banno, Eri
    De Velasco, Marco A.
    Saito, Yoshitaka
    Shimizu, Nobutaka
    Mori, Yasunori
    Minami, Takafumi
    Fujita, Kazutoshi
    Nozawa, Masahiro
    Nose, Kazuhiro
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    ANTI-CANCER DRUGS, 2022, 33 (01) : E818 - E821
  • [24] Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study
    Nukaya, Takuhisa
    Takahara, Kiyoshi
    Yoshizawa, Atsuhiko
    Saruta, Masanobu
    Yano, Yusuke
    Ohno, Takaya
    Uchimoto, Taizo
    Fukuokaya, Wataru
    Adachi, Takahiro
    Yamazaki, Shogo
    Tokushige, Satoshi
    Nishimura, Kazuki
    Tsujino, Takuya
    Nakamori, Keita
    Yamamoto, Shutaro
    Iwatani, Kosuke
    Urabe, Fumihiko
    Mori, Keiichiro
    Yanagisawa, Takafumi
    Tsuduki, Shunsuke
    Hirasawa, Yosuke
    Hashimoto, Takeshi
    Komura, Kazumasa
    Inamoto, Teruo
    Miki, Jun
    Kimura, Takahiro
    Ohno, Yoshio
    Azuma, Haruhito
    Shiroki, Ryoichi
    CLINICAL GENITOURINARY CANCER, 2024, 22 (01) : 76 - 83
  • [25] CLINICAL IMPLICATIONS AND PREDICTIVE FACTORS OF PRIMARY RESISTANCE TO NIVOLUMAB PLUS IPILIMUMAB THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Numakura, Kazuyuki
    Hatakeyama, Shingo
    Sekine, Yuya
    Yumina, Muto
    Kobayashi, Mizuki
    Kashima, Soki
    Yamamoto, Ryohei
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2023, 209 : E371 - E372
  • [26] Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
    Brown, Landon C.
    Desai, Kunal
    Wei, Wei
    Kinsey, Emily N.
    Kao, Chester
    George, Daniel J.
    Rini, Brian, I
    Ornstein, Moshe C.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [27] Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC).
    Kotecha, Ritesh
    Lee, Chung-Han
    Knezevic, Andrea
    Shah, Neil J.
    Carlo, Maria Isabel
    Feldman, Darren R.
    Patil, Sujata
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma
    Bando, Yukari
    Furukawa, Junya
    Okamura, Yasuyoshi
    Hara, Takuto
    Terakawa, Tomoaki
    Nakano, Yuzo
    Fujisawa, Masato
    ANTICANCER RESEARCH, 2022, 42 (02) : 973 - 979
  • [29] The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab
    Yoshimura, Akihiro
    Nagahara, Akira
    Ishizuya, Yu
    Yamamoto, Yoshiyuki
    Hatano, Koji
    Kawashima, Atsunari
    Nakai, Yasutomo
    Nakayama, Masashi
    Nishimura, Kazuo
    Nonomura, Norio
    Kato, Taigo
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [30] A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma
    Kijima, Yu
    Shimizu, Tomokazu
    Kato, Shinya
    Sekido, Eri
    Kano, Kana
    Toguchi, Makoto
    Horiuchi, Toshihide
    Toma, Hiroshi
    Iida, Shoichi
    Takagi, Toshio
    IJU CASE REPORTS, 2022, 5 (02) : 126 - 128
12345